CRISPR Therapeutics AG (CRSP) Common Equity (2015 - 2026)

CRISPR Therapeutics AG has disclosed Common Equity across 12 years of filings, most recently posting $1.8 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $1.8 billion, down 0.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 billion (down 0.8% YoY), and the FY2025 annual result was $1.9 billion, down 0.53% from the prior year.
• Common Equity came in at $1.8 billion for Q1 2026 at CRISPR Therapeutics AG, down from $1.9 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.2 billion in Q1 2022 to a low of $1.7 billion in Q2 2025.
• The 5-year median for Common Equity is $1.9 billion (2025), against an average of $1.9 billion.
• Peak annual rise in Common Equity reached 24.34% in 2022, while the deepest fall reached 22.24% in 2022.
• CRISPR Therapeutics AG's Common Equity stood at $1.9 billion in 2022, then advanced by 0.39% to $1.9 billion in 2023, then increased by 2.62% to $1.9 billion in 2024, then slipped by 0.53% to $1.9 billion in 2025, then fell by 5.58% to $1.8 billion in 2026.
• The last three Common Equity figures came in at $1.8 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.